LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB “Hansa“ (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of the Annual Report 2020
Sren Tulstrup, President and CEO of Hansa Biopharma, comments:
“2020 was a highly successful and transformative year for Hansa Biopharm - a year where we saw significant progress across all areas important to building a leading biopharmaceutical company: Pipeline development, medical and commercial operations and organizational development.
Most notably, we received conditional approval of Idefirix by the European Commission for desensitization treatment of highly sensitized kidney transplant patients - our first market approval. We are also very excited about our continued progress in advancing Hansa's valuable pipeline of drug candidates in therapeutic areas beyond transplantation.
In July, we achieved a landmark milestone with the exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as a potential pre-treatment prior to the administration of gene therapy for Duchenne muscular dystrophy and Limb-girdle muscular dystrophy in patients with neutralizing antibodies (NAbs) to adeno-associated virus (AAV). The partnership is progressing as planned, and in the second half of 2020 Sarepta initiated ongoing pre-clinical investigations with imlifidase in the gene therapy setting.